Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?-Reference-Cited by-同舟云学术

Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?

Published:2015-10-21 Issue:11 Volume:90 Page:1036-1040
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Zeidan Amer M.¹,Sekeres Mikkael A.²,Wang Xiao-Feng²,Al Ali Najla³,Garcia-Manero Guillermo⁴,Steensma David P.⁵,Roboz Gail⁶,Barnard John²,Padron Eric³,DeZern Amy⁷,Maciejewski Jaroslaw P.²,List Alan F.³,Komrokji Rami S.³,

Affiliation:

1. Department of Internal Medicine, Section of Hematology; Yale University and Yale Comprehensive Cancer Center; New Haven Connecticut

2. Department of Medicine; Leukemia Program, Cleveland Clinic; Cleveland Ohio

3. Department of Malignant Hematology; H. Lee Moffitt Cancer Center and Research Institute; Tampa Florida

4. Department of Leukemia; MD Anderson Cancer Center; Houston Texas

5. Department of Medical Oncology; Dana-Farber Cancer Institute; Boston Massachusetts

6. Department of Medicine; Weill Medical College of Cornell University; New York New York

7. Department of Medicine; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; Baltimore Maryland

Funder

Evans Foundation and the Aplastic Anemia and Myelodysplastic Syndromes Foundation (AAMDSF)

Publisher

Wiley

Subject

Hematology

Reference17 articles.

1. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes;Raza;Nat Rev Cancer,2012

2. There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes;Zeidan;Curr Hematol Malig Rep,2013

3. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions;Lee;Blood Rev,2015

4. Myelodysplastic syndromes: Toward a risk-adapted treatment approach;Faltas;Expert Rev Hematol,2013

5. Current therapy of myelodysplastic syndromes;Zeidan;Blood Rev,2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telomere integrated scoring system of myelodysplastic syndrome;Journal of Clinical Laboratory Analysis;2023-01-19

2. Defining the mutational profile of lower-risk myelodysplastic neoplasm patients with respect to disease progression using next-generation sequencing and pyrosequencing;Współczesna Onkologia;2023

3. Prognostic Indicators in MDS and CMML;Pathogenesis and Treatment of Leukemia;2023

4. RELATIONSHIP BETWEEN CLINICAL FEATURES OF MYELODYSPLASTIC SYNDROME AND ITS CLASSIFICATION, DIAGNOSIS AND PROGRESSION, AND PATIENT PROGNOSIS;ACTA MEDICA MEDITERR;2022

5. Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients;Annals of Hematology;2021-05-01